Pharmacokinetics of LY3871801 Following Oral Administration of a Crystalline Freebase Tablet and a Solid Dispersion Oral Suspension
Latest Information Update: 23 Mar 2022
At a glance
- Drugs Ocadusertib (Primary)
- Indications Unspecified
- Focus Pharmacokinetics
- Sponsors Eli Lilly and Company
- 17 Mar 2022 Status changed from recruiting to completed.
- 21 Feb 2022 Status changed from not yet recruiting to recruiting.
- 08 Feb 2022 New trial record